Internalizing ERB2 antibodies
US7244826B1 · kind B1 · utility
40Cited by
5References
32Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 12, 1999 |
| Grant date | Jul 17, 2007 |
| Priority date | — |
| Expiry date | Feb 12, 2019 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/812
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.